Federal officials have recently approved a new pain relief medication that aims to eliminate the risks of addiction and overdose commonly associated with opioid drugs. The U.S. Food and Drug Administration has given the green light to Vertex Pharmaceuticals’ Journavx, which is intended for short-term pain management, particularly following surgeries or injuries.
This marks the first innovative approach to pain management in over two decades, presenting an alternative to both opioids, like Vicodin and OxyContin, and over-the-counter options such as ibuprofen and acetaminophen. However, while the drug shows some effectiveness, its modest results and the challenging development process highlight the ongoing difficulties in discovering new pain relief methods.
Clinical trials involving more than 870 patients undergoing foot and abdominal surgeries indicated that Vertex’s drug offered more relief than a placebo but did not outperform a common combination of opioids and acetaminophen. Michael Schuh, a pharmacist and pain medicine expert at the Mayo Clinic, commented that although the drug’s effectiveness may not be overwhelming, it presents a promising new pathway for pain treatment.
Journavx will be priced at $15.50 per pill, significantly higher than many opioids available in generic form for about a dollar. The research for this drug began in the early 2000s, during a time when prescriptions for opioid painkillers were at an all-time high, contributing to the surge in overdose deaths. In recent years, opioid prescriptions have decreased considerably, with the current opioid crisis being largely attributed to illicit fentanyl rather than prescribed medications.
Opioids work by attaching to receptors in the brain that process pain signals, and this mechanism is what also makes them addictive. In contrast, Vertex’s drug operates differently by blocking proteins that activate pain signals before they reach the brain. Dr. David Altshuler from Vertex explained that the goal was to create pain medications without the addictive risks linked to opioids.
The side effects reported with Journavx include nausea, constipation, itching, rash, and headaches. However, Dr. Charles Argoff of Albany Medical Center noted that this new medication presents different side effects that do not carry the same risks associated with opioid use.
The concept behind Journavx was derived from research on individuals with a rare genetic condition that makes them insensible to pain. Vertex is also working on additional medications for chronic pain, which represents a broader market opportunity than acute pain management.
Despite facing challenges, including disappointing mid-stage study results for another drug targeting chronic nerve pain, Vertex remains committed to progressing with new studies in hopes of achieving better outcomes and gaining further FDA approvals.
